Cancer gene therapy using a novel secretable trimeric TRAIL. (Q40367155)

19 September 2017

Cancer gene therapy using a novel secretable trimeric TRAIL. (English)

1 reference

19 September 2017

0 references

1 reference

Kim CY

1

1 reference

19 September 2017

Jeong M

2

1 reference

19 September 2017

Mushiake H

3

1 reference

19 September 2017

Kim BM

4

1 reference

19 September 2017

Kim WB

5

1 reference

19 September 2017

Ko JP

6

1 reference

19 September 2017

Kim MH

7

1 reference

19 September 2017

Kim M

8

1 reference

19 September 2017

Kim TH

9

1 reference

19 September 2017

Robbins PD

10

1 reference

19 September 2017

Billiar TR

11

1 reference

19 September 2017

Seol DW

12

1 reference

19 September 2017

1 February 2006

1 reference

19 September 2017

1 reference

19 September 2017

13

1 reference

19 September 2017

4

1 reference

19 September 2017

330-338

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.gt.3302658

19 September 2017

0 references

cites work

Death receptors: signaling and modulation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

Apoptosis by death factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

Caspases: intracellular signaling by proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

The receptor for the cytotoxic ligand TRAIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

The death domain kinase RIP mediates the TNF-induced NF-kappaB signal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

Identification and characterization of a new member of the TNF family that induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

Safety and antitumor activity of recombinant soluble Apo2 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

Lethal effect of the anti-Fas antibody in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

The secretable form of trimeric TRAIL, a potent inducer of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

Furin/PACE/SPC1: a convertase involved in exocytic and endocytic processing of precursor proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

APO2 ligand: a novel lethal weapon against malignant glioma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

Gene therapy for malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

Viral vectors for gene transfer: a review of their use in the treatment of human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): a phase I trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

inferred from DOI database lookup

7 January 2021

based on heuristic

TRAIL triggers apoptosis in human malignant glioma cells through extrinsic and intrinsic pathways.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

inferred from DOI database lookup

7 January 2021

based on heuristic

Gene therapy for head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302658

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.GT.3302658

1 reference

Dimensions Publication ID

19 September 2017

0 references

1 reference